“Delaware Supreme Court Urged to Review Ruling in Zantac Case, Potentially Paving Way for Mass Tort Surge”

Defendants in Delaware’s Zantac litigation have moved for the state Supreme Court to review a Superior Court ruling that endorses the testimony of plaintiffs’ experts. This decision, they argue, puts state Daubert standards in conflict with those of federal courts and previous state decisions. They caution that, should Judge Vivian Medinilla’s May 31 order stand, the floodgates could open for mass tort plaintiffs to seek a favorable venue in Delaware. Such an influx of cases could significantly impact the efficient administration of justice in both Delaware-domiciled companies and Delaware residents.

The defendants, including pharmaceutical giants GlaxoSmithKline, Pfizer, Sanofi, and Boehringer Ingelheim, represented by lead national counsel from Dechert, Williams & Connolly, DLA Piper, and King & Spalding, respectively, filed an application for interlocutory review on June 10. They stated that adherence to Medinilla’s order could lead to an undesirable surge of mass tort litigation in the state. Details of the May 31 order can be reviewed in the court’s opinion document.

For further context, you can access the original article here.